In this free webinar, participants will be introduced to a variety of these statistical tools, learn about the kinds of impact they can provide and hear about some key questions/considerations that should be asked before starting a rare disease trial.
Walter Boyle, MS, Global Head of Biostatistics & Programming, Synteract
Walter Boyle is a biostatistician with over 15 years of experience analyzing, exploring and explaining clinical and healthcare data. His work encompasses a wide range of indications including multiple sectors such as public health, life sciences, healthcare and analytical software development. Walter has experience working with a variety of people, solving a diverse set of problems. Currently, Walter is responsible for the overall management and strategic direction of the Biostatistics and Programming department at Synteract, a role which is equal parts project work, consulting, business development and management.
Walter received his undergraduate degrees in Statistics and Applied Mathematics from North Carolina State University and his Master’s degree in Biostatistics from the School of Public Health at the University of North Carolina at Chapel Hill.Message Presenter
Who Should Attend?
VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
Participants will learn about:
- General working understandings of a selection of advanced statistical concepts
- The positive, and potentially negative, ways these concepts can impact clinical trials
- How to engage with team members to make sure the right questions are being asked
With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy, and rare/orphan disease studies.